Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:53:13.086Z.
Consensus retrieved: 2026-10-06T16:37:08.247Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:53:13.086Z.
Quote observation: 2026-10-06T18:50:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2f01081ea3fc0a51e4cf91d063b31ee616ec5173ab430d737d4f5d2ff49fd95f
Forward PE Ratio (N/A) = Dated Quote Price ($1.20) / Consensus Forward EPS ($-0.58)
FORWARD PE RATIO
N/A
Spero Therapeutics, Inc.
Market Cap
$69.48M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | $69.48M | N/A |
| Tiziana Life Sciences Ltd (TLSA)vs › | $68.72M | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $68.60M | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $68.08M | 49.00 |
| MindWalk Holdings Corp. (HYFT)vs › | $71.36M | N/A |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $71.81M | N/A |
| Cingulate Inc. (CING)vs › | $67.01M | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $72.09M | N/A |
| iBio, Inc. (IBIO)vs › | $66.28M | N/A |
| XBiotech Inc. (XBIT)vs › | $65.88M | N/A |
Trailing P/E
10.9
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.20, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.58 | $-0.58 – $-0.58 | 1 | n/m |
| 2027-12-31 | $-0.88 | $-0.88 – $-0.88 | 1 | n/m |
| 2028-12-31 | $-0.12 | $-0.12 – $-0.12 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
